Stock Watch: Pharma And Anti-Pharma
How Merck And Pfizer Polarized Second-Quarter Earnings
While not direct competitors in all therapeutic areas, Pfizer’s and Merck’s sales offered some stark contrasts in the second quarter.
You may also be interested in...
The pandemic distorted much in drug and diagnostic companies’ quarterly financial reports, but that time is over and investors now applaud organic revenue growth.
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.